Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis
Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...
Others
CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage
CanSino Biologics Inc. (HKG: 6185) announced the initiation of its Phase I/II clinical study for...
Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
A federal jury in the U.S. District Court for the District of Massachusetts returned a...
UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
UCB (EBR: UCB) announced today Week 16 data from the BE BOLD Phase III clinical...
Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs – Patients Bear Excess Costs Above Winning Prices
The Shanghai Municipal Healthcare Security Bureau issued the “Notice on Optimizing Payment Coordination for the...
Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...
Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development
Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...
Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition
Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...
Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China
Cue Biopharma Inc. (NASDAQ: CUE) announced an exclusive licensing agreement with Ascendant Health Sciences Ltd.,...
GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...
Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s...
Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus...
Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory...
AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
AstraZeneca PLC (NYSE: AZN) reported first-quarter 2026 financial results with total revenue of USD 15.288...
Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced this week that Botox has received marketing...
Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
Huahui Health, a Beijing-based biotechnology company focused on viral hepatitis, hepatology, and oncology, announced a...
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on...
Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues...
Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....
China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework
China’s National Health Commission (NHC) released a draft notification for public consultation on comprehensive revisions...